Although the pathogenic mechanisms underlying axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) are not fully elucidated, several lines of evidence suggest that immune responses mediated by interleukin 17A (IL-17A) play a pivotal role in both diseases. This is best highlighted by the significant clinical efficacy shown with inhibitors of IL-17A in treating axSpA and PsA. Nevertheless, a number of knowledge gaps exist regarding the role of IL-17A in the pathophysiology of spondyloarthritis in man, including its cellular origin, its precise role in discrete disease processes such enthesitis, bone erosion, and bone formation, and the reasons for the discrepant responses to IL-17A inhibition observed in certain other spondyloarthritis manifestations. In this review, we focus on the latest data from studies investigating the role of IL-17A in ankylosing spondylitis (AS) and PsA that build on existing and emerging scientific knowledge in the field. Key remaining research questions are also highlighted to guide future research.
- ankylosing spondylitis
- psoriatic arthritis
This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
The spondyloarthritides (SpA) comprise related but phenotypically distinct inflammatory diseases including psoriatic arthritis (PsA), non-radiographic axial spondyloarthritis (nr-axSpA) and radiographic axSpA (ankylosing spondylitis (AS)), arthritis associated with inflammatory bowel disease (IBD), reactive arthritis, juvenile idiopathic arthritis and acute anterior uveitis.1–3 The SpA diseases share common immunological and inflammatory components and present with overlapping clinical phenotypes.4–7 Indeed, multiple genetic polymorphisms within the interleukin (IL)-23/17 axis have been implicated across SpA.8–11 Intriguingly, despite the clinical and genetic similarities, these disorders are showing emergent and unexpected heterogeneity with respect to IL-23/17 axis therapeutic manipulation, a topic addressed later in this article.
IL-17A, a member of the IL-17 superfamily of cytokines, is known to play an important role in SpA manifestations related to the skin, joints and entheses, as reflected by the suppression of disease activity seen with IL-17A inhibitors in psoriasis, PsA and AS.12–19 However, in other settings where IL-17 family members have been found at sites of disease, such as gut inflammation and uveitis, IL-17A inhibition is not beneficial.20–22 These discrepant responses illustrate the need for clearer understanding of the aetiology of these inflammatory diseases, particularly the role of the IL-17 family in the context of the tissue(s) affected. IL-17 research has accelerated rapidly, with nearly 10 000 articles published on this topic in the last 5 years alone. In this article we highlight the latest breakthroughs that expand understanding of the role of IL-17A in both homoeostasis and in disease in axSpA and PsA.
IL-17A production and signalling
The IL-17 superfamily consists of six ligands (IL-17A to IL-17F), which can bind to five receptor subtypes (IL-17RA to IL-17RE). The basic biology of most of the IL-17 superfamily has been reviewed extensively elsewhere.23 24 IL-17A, the prototypical ligand, is by far the best characterised member of the IL-17 family and can exist as a homodimer or in a heterodimer with IL-17F and signals through an obligate dimeric IL-17RA and IL-17RC receptor complex.24 On binding to a receptor, IL-17A upregulates inflammatory gene expression either by inducing de novo gene transcription or by stabilising mRNA of pro-inflammatory cytokines and chemokines.24
Well-defined role of IL-17A in host defence
In healthy individuals, IL-17A, as well as other members of the IL-17 family, functions in host defence against a range of bacterial and fungal pathogens at epithelial and mucosal barriers in the skin, colon and airways.25–27 Although the exact interplay between the various IL-17 family members is poorly understood, epithelial cell-derived (especially IL-17C) and haematopoietic cell-derived IL-17s (IL-17A and F) may have complementary functions in response to pathogens, with the former predominantly enhancing barrier function and the latter propagating the inflammatory response.28 The IL-23/17 axis co-ordinates barrier function in the skin and the gut, both of which are sites of either physical or chemical stress and are also sites of complex microbiotal interactions. What might the common denominator be between the IL-23/17 axis and inflammation at the sterile skeletal locations afflicted by SpA-associated pathology? We agree with the assertion that the IL-23/17 axis might be adapted to facilitate homoeostasis at these highly mechanically stressed entheseal sites that are prone to microinjury.29
An array of genetic defects in the IL-17 pathway, identified through human translational immunology, collectively point towards a role in anti-fungal immunity (table 1). Chronic mucocutaneous candidiasis (CMC) is a hallmark of individuals with genetic defects affecting IL-17 immunity, manifesting as recurrent or persistent infections of the skin, nails and mucosae with Candida albicans, with or without other clinical signs.30 As can be seen from table 1, these syndromes result from genetic defects affecting several immune processes, with the commonality being that the defects involve more than one cytokine or immune function. The genetic defects that are often shared between the IL-12 and the IL-23 pathway that are upstream of the IL-17 pathway are not linked to fungal infection but may be linked to mycobacterial infections consequent to impaired interferon gamma signalling.31
Preclinical and ex vivo studies also implicate IL-17A in immunity against a range of other pathogens including bacteria such as Escherichia coli, fungi such as Cryptococcus neoformans, parasites such as Trypanosoma cruzi, and viruses such as influenza (reviewed in Matsuzaki and Umemura).28 Although as with all drugs that modulate immune response there is the potential for an increased infection risk with IL-17A inhibitors, clinical data show no risk from specific pathogens, with the exception of candidiasis.18 19 32–35 Reassuringly, no association between mycobacterial disease and blockade of IL-17A biological activity has been observed in man.34
Role of IL-17A in SpA
Although IL-17A cytokine expression has been detected in a multitude of autoimmune and autoinflammatory diseases, a key role in psoriasis, PsA and axSpA is evident.
Although a detailed examination of the genetic basis of SpA is outside the scope of this article (reviewed in detail in Taams et al and Brown et al),11 36 the strongest association with genetic susceptibility to axSpA and PsA lies within the MHC class I region and in particular the HLA-B27 region.8–10 Multiple immunological functions can be altered by these genetic associations, including several relevant to IL-17A signalling through activation of CD8+T cells and CD4+T cells.11 37–40 Several single nucleotide polymorphisms in genes directly involved in IL-17 signalling have also been linked to AS and PsA (figure 1), including variants in the IL-12 p40 subunit, the IL-23 p19 subunit, the IL-23 receptor, IL-17A and IL-17RA.41–48 Additional susceptibility variants have been identified in genes encoding IL-17-related signalling molecules including TYK2, TRAF3IP2 and STAT3.43 44 47 49–53
There has been significant interest in identifying the sources of IL-17A in SpA and a number of innate and adaptive immune system cell types have been implicated (reviewed in Taams et al) (figure 2).11 Increased levels of type 3 innate lymphoid cells (ILC3) have been identified in blood and synovia of patients with SpA, and these levels correlate with PsA disease activity.54 55 Recently, resident populations of both ILC3 and γδ T cells have been identified at the human enthesis for the first time where they may produce the IL-17A that drives enthesitis, a key early pathological lesion in SpA.56–59 Recent studies have also reported increased numbers of IL-17+invariant natural killer T (iNKT) cells and γδ T cells in SpA patient peripheral blood.60 Indeed, these RORγt+innate like T cells, and not conventional T cells, represented about half of all IL-17 producing blood circulating T cells and were further skewed towards IL-17 expressing subsets in synovial fluid samples, as determined by both advanced cytometric methodologies and intracellular cytokine IL-17 staining.60 In vivo evidence for enrichment of pathogenic subsets in the joints was recently shown in mannan-induced arthritis in SKG mice, an IL-23/17 axis dependent disease.61
Tissue-resident memory T cells (TRM) represent approximately 50%–70% of the pool of resident T cells in healthy skin, and can produce a variety of cytokines, including IL-17A.62–64 In patients with psoriasis, IL-17-producing CD8+TRM cells have been identified in non-involved skin and may be involved in recurrence of psoriasis at sites of prior resolution.62–64 Efforts are ongoing to investigate the role of TRM cells in tissues affected by SpA. A study in patients with PsA has shown the presence of IL-17 expressing CD4- (CD8+) T cells in the synovium.65 However, no studies have been reported in axial disease to date.
Adaptive immune cells are key drivers of chronicity in SpA and as such, are also a major source of IL-17A. The presence of T helper 17 (Th17) cells in SpA is relatively well established.66 Increased levels of both Th17 cells and IL-17A are found in skin lesions and the blood of patients with psoriasis as well as the blood and synovial fluid of patients with AS and PsA.67–75 IL-17A initiates several feedback-loop mechanisms in SpA leading to increased expansion of Th17 cells and thereby further production of IL-17A.76 Evidence suggests that there are distinct subtypes of Th17 cells whose differentiation is dependent on specific combinations of cytokines.77 Furthermore, there is likely to be considerable plasticity between Th17 cells and FOXP3+regulatory T cells.78 Identification of the subtype(s) of Th17 cells and their regulation and relevance to axSpA and PsA is an important topic of ongoing research.
Although not found in rheumatoid arthritis synovial fluid, IL-17A-producing conventional CD8+T cells are present in synovial fluid of inflamed joints in patients with AS and PsA where their levels correlate with disease activity.71 72 79 IL-17-producing mucosal-associated invariant T (MAIT) cells have been identified in skin and blood from patients with psoriasis80 and are also increased in the synovial fluid and blood of patients with AS, where they produce IL-17A in an IL-7-dependent fashion.81 82
It has been suggested that neutrophils contribute to the amplification of the inflammatory response in SpA by producing further IL-17A and although IL-17A-positive neutrophils have been reported in psoriatic skin, the synovium of patients with PsA, and in AS facet joints,83–88 the emerging consensus is that neutrophils do not produce IL-17A mRNA or protein, even after strong stimulation with various cytokine combinations.89 Similarly, although IL-17A-positive mast cells have been found in synovial tissue from patients with SpA,90 the concept is of exogenous IL-17A capture and release, as opposed to synthesis.91 A recent study indicated that levels of IL-17A were higher in joint-resident mast cells following IL-17A inhibition, which supports the concept of storage of this cytokine under normal tissue homoeostasis and mast cell release during inflammation.92
A key research question for the future will be identifying all IL-17A-producing populations, especially at the enthesis in SpA. It is noteworthy that measurement of serum levels of IL-17A is likely to be of minimal relevance due to the local tissue responses seen in SpA via IL-17A-producing resident cells.
Considerable recent developments have occurred in experimental enthesitis research where high mechanical stressing at entheses is associated with local immune system activation.59 93 94 Non-SpA-related enthesitis can result from repeated mechanical strain in healthy individuals (eg, tennis elbow) and usually resolves spontaneously, whereas inflammation in SpA shows chronicity.59 The underlying mechanisms behind this pathologically exaggerated immune response, which is driven by a combination of genetic factors and disturbed epithelial barrier function, are starting to be unravelled.59 95–97
Enthesitis is triggered predominantly by an innate immune response. Prostaglandin E2 (PGE2) and IL-23 may be important early mediators, activating resident immune cells to produce IL-17A and other inflammatory cytokines. Indeed, peri-entheseal bone involvement and the often excellent responses observed with NSAIDs incriminate PGE2 in axial disease.59 In mice, hepatic expression of IL-23 induces spondyloarthropathy by acting on ROR-γt+CD3+CD4-CD8- entheseal resident T cells to produce inflammatory mediators including IL-17A.98 γ/δ T cells have been shown to constitute the large majority of murine IL‐17A producing cells, proliferating at the site of injury, and enhancing bone regeneration.99 100 However, although enthesitis appears to be a cardinal lesion in several IL-23/17 axis murine models of inflammatory arthritis,101–107 other models have indicated that disease can arise in a T-cell independent manner including that mediated by TNF production from entheseal myeloid and stromal cells.94 108–110
In humans, IL-17A-producing enthesis-resident ILC3 and γδ T cells have recently been described.56–58 Resident myeloid cells that can locally produce IL-23 have also been described,111 and their numbers in man may be linked to mechanical load.108 IL-17A likely acts as an amplifier of enthesitis, inducing several other cytokines by resident mesenchymal cells.98 112 113 Prolonged entheseal inflammation leads to new bone formation and also, to a much lesser extent, bone erosion, and is subject to considerable research interest.59
Preclinical and clinical data suggest that bone erosion and new bone formation in SpA may occur simultaneously at different anatomical sites,114–117 with IL-17A playing a complex role in these processes.
Numerous preclinical studies have indicated that IL-17A promotes bone resorption in experimental arthritis.118–121 Recent efforts have focused on elucidating the mechanisms behind these effects and indicate that IL-17A stimulates receptor activator of nuclear factor-kB ligand (RANKL) expression and inhibition of Wnt signalling, thereby inhibiting osteoblast activity (figure 3).122–128
Clinical data in patients with PsA show a significant reduction in joint radiographic progression with IL-17A inhibitors versus placebo in the short-term and low long-term rates of radiographic progression.13 14 129 Furthermore, recent data from the PSARTROS study showed no progression of catabolic and anabolic bone changes in the joints of patients with PsA treated with secukinumab for 24 weeks.130
New bone formation
The precise role of IL-17A in new bone formation in axial SpA and PsA is currently unknown, with contradictory experimental findings observed. Studies favouring a role in new bone formation include data from both animal models and human primary cells (summarised in figure 3). IL-17A has been reported to boost osteogenesis via enhancing osteoblast differentiation from local mesenchymal stem cell populations,100 131–133 and the subsequent activation of the osteoblasts via activation of the JAK2/STAT3 signalling pathway, which is associated with osteogenesis.131 IL-17A knockout models have been associated with impaired bone regeneration at both 14 and 21 days post a drill-hole fracture in the femur when compared with wild type mice.100 Furthermore, in the mycobacterium tuberculosis-induced diseased HLA-B27 transgenic rat model of SpA, IL-17A blockade significantly suppressed pathological new bone formation.134 In humans, IL-17A levels are elevated in the days following fracture, which in turn is associated with callus formation.135
In contradistinction, cutaneous-restricted overexpression of IL-17A was associated with bone loss in murine models.136 Moreover, rat calvarial defects show impaired healing when exposed to IL-17A, combined with significant impairments in osteogenesis in the isolated cells when exposed to IL-17A.137 In vivo, IL-17A is associated with osteoclastogenic activation and systemic bone loss in rheumatoid arthritis.122 124 Thus, determining the role of IL-17A in new bone formation remains an important avenue of future research.
The immune system plays a critical role in modulating acute and chronic pain in both the peripheral and central nervous systems.138 139 Although pain in SpA is often assumed to be a surrogate marker for inflammation, evidence is emerging to suggest a more complex picture. In axSpA, pain does not always correlate with inflammation or radiographic measures of disease.140 Furthermore, neuropathic pain as well as inflammatory pain has been observed in patients with AS and PsA.141 142
IL-17A can modulate inflammatory pain by directly increasing nociceptor excitability and potentiating hyperalgesia through the induction of secondary factors.139 143–146 Both IL-17RA and IL-17RC are expressed in murine neuronal tissue where they contribute to inflammatory responses.147 148 Preclinical studies also suggests a role for IL-17A in neuropathic pain.149–152 Clinical data with inhibitors of IL-17A in AS and PsA show rapid and significant pain reduction,153 154 but work to assess whether this represents a reduction in neuropathic as well as inflammatory pain is needed.
Gut inflammation in SpA
The role of IL-17A in IBD and its potential link to the pathogenesis of axSpA and PsA has been the subject of some controversy. Historically, preclinical data investigating the outcome of IL-17A inhibition in mouse IBD models have been inconsistent, with some studies showing disease protection and others showing exacerbation.155 156 Clinically, IL-17A inhibition was ineffective in moderate-to-severe Crohn’s disease.20 Long-term clinical trial and postmarketing safety data in psoriasis, PsA and AS indicate that the overall incidence of IBD is low, within the expected range in these disorders, and not exacerbated by secukinumab treatment.157 This highlights one of the pitfalls of translating preclinical data to a clinical setting and has led researchers to reconsider the preclinical IBD models. Nevertheless, long-term data with IL-17A inhibitors in clinical practice are required to investigate this issue further.
The γδ T cell was the principal source of gut-derived IL-17A in a mouse model of colitis, where IL-17A-dependent regulation of the tight junction protein occludin during epithelial injury was shown to maintain barrier integrity.158 Mucosal tissues have also emerged as a key physiological site for the differentiation and regulation of Th17 cells.77 159 160 A role for ILC3 and innate-like T cells such as iNKT cells and MAIT cells in IBD is also postulated based on their high representation at barrier sites.161–163 Putative links have also been suggested between gut inflammation, migration and accumulation of IL-17A-producing ILC3 cells in the joints of patients with AS.164 A recent study also found that pathogenic bacteria can induce intestinal barrier defects and translocate to systemic organs, triggering autoimmune disease.165
Like IBD, anterior uveitis in SpA shares common genetic risk factors and the involvement of certain pro-inflammatory cytokines. Clinical trials have demonstrated the efficacy of anti-TNF monoclonal antibody therapy in panuveitis or posterior uveitis but clinical trials with inhibitors of IL-17A have failed to meet their primary endpoints for these forms of the disease that are pathophysiologically distinct from anterior uveitis.21 Both IL-17A and IL-17F have been detected in anterior uveitis (reviewed in Weinstein and Pepple), but whether they play a critical role is unclear.166 In secukinumab-treated AS patients there was no evidence suggesting uveitis flares in patients with previous anterior uveitis.167 Further research is required to extend our understanding of the precise role of IL-17A in the pathogenesis of anterior uveitis.
Targeting IL-17A in SpA
The key role played by IL-17A in the pathogenesis of AS and PsA is highlighted by the efficacy shown by inhibitors of IL-17A in clinical trials. Secukinumab, a fully human anti-IL-17A monoclonal antibody, is approved for the treatment of psoriasis, PsA and AS based on the results of several large randomised controlled trials.12–16 168 Ixekizumab, a humanised anti-IL-17A antibody, is approved for the treatment of psoriasis and PsA and has shown significant efficacy in two large phase III trials in AS.17–19 169 170 The efficacy of IL-17A inhibitors across all manifestations of disease in AS and PsA, including skin, nails, peripheral arthritis, axial disease, dactylitis and enthesitis, highlights the utility of drugs targeting this pathway (figure 4). Inhibitors of IL-17A have also been shown to have an overall favourable long-term safety profile in clinical trials,32 33 35 including low rates of serious infections, Candida infections and malignancy, with no evidence of increased suicidality or IBD exacerbation above expected background levels.157 Nevertheless, the long-term safety of IL-17A inhibitors will need to be monitored in a real-world setting.
What is the basis for divergent IL-17A and IL-23 responses in axial disease?
IL-23 plays a key role in amplifying and maintaining IL-17A production in many cells, so it was expected that IL-23 inhibitor therapy would have similar results to IL-17A inhibition in axSpA. Interestingly, clinical studies with ustekinumab, an IL-12/-23 inhibitor, in axial SpA were terminated due to lack of efficacy171 and the IL-23 p19 inhibitor risankizumab also failed to show efficacy in AS in a phase II proof of concept study.172 Conversely, the efficacy of IL-17A inhibition in AS suggests that IL-17A and not IL-23 is the major cytokine mediating disease pathogenesis in axSpA and in this context, IL-17A is likely to be produced in a largely IL-23-independent manner. Understanding the reasons for these divergent roles of IL-23 and IL-17A in the pathophysiology of axSpA is one of the hottest topics in current IL-17A research. Emerging evidence suggests there may be anatomical and immunological differences between axial and peripheral enthesitis and subsequent downstream disease manifestations (figure 5). For instance, there is generally more entheseal soft tissue inflammation or synovio-entheseal complex disease in peripheral enthesitis in PsA,173 and more peri-entheseal osteitis in the spine in AS, with this bone proclivity being linked to carriage of the HLA-B27 gene for axial disease.174 In terms of control of IL-17 production, IL-23 receptor positive and negative subpopulations of γδ T cells have been identified in human spinous processes entheses, pointing to a role for IL-23-independent IL-17A production,57 and enthesis-resident myeloid cells are capable of IL-23 production locally.111 Further research is required to investigate the drivers of this process in the future although data in mice indicate that the initiation, but not the persistence, of experimental SpA is dependent on IL-23.175
The IL-17A inhibitors show efficacy in treating multiple facets of SpA, including psoriasis, enthesitis, synovitis, bone erosion, new bone formation and pain, which illustrates the importance of IL-17A in disease pathophysiology. Future research will investigate key remaining gaps, such as the role of human enthesis-resident innate and adaptive T cells in SpA and our understanding of IL-23-independent IL-17A production. The ongoing assessment of IL-17A inhibitors in a real-world setting will also be important as these agents become more widely prescribed in clinical practice. Ongoing research efforts will attempt to answer these and other open questions and shed further light on the role of IL-17A in SpA in the hope of furthering our understanding and improving treatment of these diseases.
The authors would like to acknowledge the following individuals for their help in the preparation of this work: Darren Asquith and Lindsey Hanson from Novartis UK.
Handling editor Josef S Smolen
Correction notice This article has been corrected since it published Online First. The last sentence in the second paragraph of the 'Well-defined role of IL-17A in host defence' section has been updated for clarity.
Contributors All authors provided a substantial contribution to the conception, design and interpretation of the work, drafted the work or revised it critically for important intellectual content, and provided final approval of the submitted version of the manuscript.
Funding Medical writing support was provided by Ben Drever from Seren Communications, an Ashfield Company, part of UDG Healthcare, the funding for which was provided by Novartis.
Competing interests RM reports grants and personal fees from Novartis, during the conduct of the study. DGM reports grant and personal fees from Novartis, outside the submitted work. IBM reports personal fees from AbbVie, grants and personal fees from BMS, personal fees from Celgene, grants and personal fees from Janssen, personal fees from Lilly, personal fees from Novartis, grants and personal fees from UCB, personal fees from Leo, grants from Astra Zeneca, grants from Boehringer Ingelheim, outside the submitted work; BWK reports grants and personal fees from AbbVie, grants and personal fees from Eli Lilly & Co, grants and personal fees from Novartis, grants from Roche, grants from UCB, personal fees from Janssen, personal fees from Pfizer, personal fees from Sandoz, outside the submitted work. JS reports personal fees from AbbVie, personal fees from BMS, personal fees from Celgene, personal fees from Janssen, personal fees from Novartis, personal fees from UCB, personal fees from Merck, outside the submitted work.
Patient consent for publication Not required.
Provenance and peer review Not commissioned; externally peer reviewed.